Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity
Afucosylated IgG는 외피 바이러스 반응을 특성화하고 COVID-19 심각성과 상관 관계가 있습니다.
Research Article
[키워드] acute phase
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
ADCC
amplify
amplifying
anti–SARS-CoV-2 IgG
antibody
antibody-dependent cellular cytotoxicity
anticancer
Antigen
antigens
Antiviral
association
Attenuated Virus
B cell
B cell response
binding
Blood
blood cell
Blood cells
Blood Group
C-reactive protein
C-reactive protein (CRP
cause
Cell
cellular
circumvent
Clinical outcome
complement
Concentration
condition
conserved
coronavirus
COVID-19
COVID-19 patient
COVID-19 patients
Critical
Critically ill
critically ill COVID-19 patients
cytokine
Cytokine storm
dengue virus
destruction
determined by
disparate
domain
domains
elevated
Exacerbation
example
excessive inflammation
Fc receptor
Fc receptors
FcγRIIIa
foreign antigen
foreign antigens
fucose
functions
glycoprotein
Glycoproteins
glycosylation
help
hepatitis B
Hepatitis B virus
HIV
host cell
host cells
humans
Hypothesis
IgG
IgG antibody
IgG immune response
IgG response
IgG responses
IL-6
Immune cell
immune response
immune responses
Immune-mediated
Immunoglobulin
Immunoglobulin G
in some
in vitro
individual
individuals
induce
initiate
interleukin-6
invading pathogens
investigated
isotype
Macrophage
macrophages
membrane
Mild disease
mild symptoms
mRNA vaccines
myeloid cells
natural infection
natural killer
occur
over
Pathogens
Pathologies
pathology
Patient
patients
plasma
position
proinflammatory
Proinflammatory cytokine
promote
promoted
Protective
Protein
Protein subunit
receptor
receptors
Region
report
reported
required
respiratory
response
responses
responses against
SARS-CoV-2
Science
Seroconversion
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
severe COVID-19
severe symptom
severe symptoms
severity
strength
subclass
subunit
sugar
surface protein
target
target cell
target cells
tested
therapeutic
therapeutic antibodies
Treatment
Trigger
vaccination
Vaccinations
Vaccine
variant
Viral
Viral load
virus
viruses
with COVID-19
with mild disease
[DOI] 10.1126/science.abc8378 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1126/science.abc8378 PMC 바로가기 [Article Type] Research Article